Incyte

$80.86
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.65 (-0.80%) Today
+$0.12 (+0.15%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell Incyte and other stocks, options, and ETFs commission-free!

About INCY

Incyte Corp. Common Stock, also called Incyte, is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE. The listed name for INCY is Incyte Corp. Common Stock.

CEO
Hervé Hoppenot
Employees
1,456
Headquarters
Wilmington, Delaware
Founded
1991
Market Cap
17.68B
Price-Earnings Ratio
Dividend Yield
Average Volume
1.31M
High Today
$82.11
Low Today
$80.63
Open Price
$81.24
Volume
1.04M
52 Week High
$110.37
52 Week Low
$62.48

Collections

INCY Earnings

-$2.86
-$1.49
-$0.13
$1.24
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 16, Pre-Market

You May Also Like